Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2025.11.05

Where Nature Inspires Innovation: University of Kansas Prof. Apurba Dutta visits Sai

Dr. Apurba Dutta, Associate Professor at Department of Medicinal Chemistry, University of Kansas, USA, recently visited our Sai Life Sciences campus to deliver a masterclass on “A serine-derived second-generation chiron: Applications in the synthesis of natural and nature-like molecular scaffolds.”
During the session, he explored how simple natural molecules can serve as versatile building blocks for designing complex, biologically relevant compounds. He shared insights into nitrogen-containing molecules, which play a crucial role in many medicinally important compounds, and discussed strategies for synthesizing them efficiently with high precision.


The masterclass offered a unique opportunity for our teams to learn directly from a leading academic expert, gaining fresh perspectives on how nature inspires innovation in medicinal chemistry.
Dr. Dutta’s research focuses on the design and synthesis of bioactive natural and non-natural compounds targeting anti-infective and anti-cancer pathways. His work spans asymmetric synthesis, chiral methodologies, and medicinal chemistry applications. He received his Ph.D. from the North-Eastern Hill University, Shillong, India (1989). Subsequently he was an Alexander von Humboldt post-doctoral fellow at the University of Konstanz, Germany (1991-1992) followed by a second post-doctoral stint at the University of Kansas, USA (1993-1995).


At Sai, we value such interactions with academic leaders, as they enrich our scientific approach and strengthen our commitment to continuous learning, collaboration, and the discovery of new solutions in drug development.

Share article

More News

2026.03.10

AI-driven retrosynthesis integrated into Discovery Chemistry

Sai Life Sciences has entered into a collaboration with Chemical.AI, a technology company specialising in computer-aided synthesis design, to integrate an AI-driven retrosynthesis platform into its Discovery Chemistry workflows. The integration enables medicinal chemists to evaluate synthetic routes more rapidly and explore a broader set of feasible pathways during early-stage drug discovery. Retrosynthesis is a […]
Read more

2026.03.10

Structural Biology capabilities launched with X-Ray Crystallography

Sai Life Sciences has introduced integrated structural biology capabilities with the establishment of X-ray protein crystallography workflows to support structure-based drug discovery programs. The platform encompasses end-to-end protein engineering capabilities, including construct design, gene synthesis, and in-house recombinant protein expression and purification. These foundational steps enable generation of high-quality protein material suitable for structural and […]
Read more

2026.03.09

New Medicinal Chemistry block set for inauguration in Hyderabad

A new Medicinal Chemistry block, Unit VIII, is set for inauguration at IKP, Genome Valley, Hyderabad, expanding discovery capacity to meet growing program demand. The four-floor facility spans approximately 100,000 sq. ft. and is designed to support large, multi-disciplinary project teams. It accommodates more than 200 fume hoods and includes a tightly integrated analytical laboratory […]
Read more

2026.03.09

AI-enabled production and material planning platform implemented

Over the past several months, focused AI pilot initiatives have been conducted across operations to evaluate practical applications that strengthen execution. One such initiative is now live across the network: Optimus, an integrated AI-enabled production and material planning platform, implemented at the end of December 2025. Optimus consolidates capacity planning, equipment allocation, and material availability […]
Read more

2026.03.09

Commercial-scale Photo Flow Chemistry successfully executed in Bidar

Commercial-scale flow chemistry has been successfully executed at our API manufacturing site in Bidar for a late-phase program supporting a US-based innovator. This execution builds on prior investments in continuous processing infrastructure at the site, including a 3-litre photo flow reactor equipped with a monochromatic blue LED light source. The platform enables controlled photochemical transformations […]
Read more